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ABSTRACT: Aging promotes a range of degenerative pathologies characterized by progressive losses of tissue 
and/or cellular function. Fibrosis is the hardening, overgrowth and scarring of various tissues characterized by 
the accumulation of extracellular matrix components. Aging is an important predisposing factor common for 
fibrotic heart and respiratory disease. Age-related processes such as senescence, inflammaging, autophagy and 
mitochondrial dysfunction are interconnected biological processes that diminish the regenerative capacity of the 
aged heart and lung and have been shown to play a crucial role in cardiac fibrosis and idiopathic pulmonary 
fibrosis. This review focuses on these four processes of aging in relation to their role in fibrosis. It has long been 
established that the heart and lung are linked both functionally and anatomically when it comes to health and 
disease, with an ever-expanding aging population, the incidence of fibrotic disease and therefore the number of 
fibrosis-related deaths will continue to rise.  There are currently no feasible therapies to treat the effects of chronic 
fibrosis therefore highlighting the importance of exploring the processes of aging and its role in inducing and 
exacerbating fibrosis of each organ. The focus of this review may help to highlight potential avenues of 
therapeutic exploration 
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Fibrosis is the formation of fibrous connective tissue in 
response to injury. It is characterized by the accumulation 
of extracellular matrix (ECM) components, particularly 
collagen, at the site of injury. Fibrosis is a vital component 
of wound healing and tissue repair, although, continued 
activation is highly detrimental and a common 
pathological process in cardiovascular and respiratory 
disease [1]. The primary cellular and molecular actions of 
fibrotic diseases share many functional similarities, 
despite differences in etiology and clinical outcome [2]. 
At its core, chronic fibrosis is defined by the overgrowth, 
hardening and scarring of tissues due to continuous 
  Volume 10, Number 2; 419-428, April 2019                       
 Murtha LA., et al                                                                                           Aging in cardiac and pulmonary fibrosis 
 
Aging and Disease • Volume 10, Number 2, April 2019                                                                               420 
 
wound-healing which can effect multiple organ systems 
including but not limited to the heart, lung, kidney, liver, 
and skin [3]. We previously reported that fibrosis of the 
heart and lung make up a significant proportion of 
fibrosis-related deaths [1], in this review we will focus on 
the role of aging in the heart and lung.  
Aging is a predisposing factor for cardiac and 
pulmonary fibrosis, with the prevalence of heart failure 
and fibrotic respiratory diseases such as idiopathic 
pulmonary fibrosis (IPF) increasing dramatically with 
advancing age [4, 5]. The aging of cardiac and lung tissue 
ultimately results in structural remodeling of the 
extracellular matrix caused by alterations in the 
concentration and organization of ECM components such 
as collagen and elastin [5-7]. Biological aging is 
accelerated by the cumulative damage and stress that 
occurs during a lifetime. This premature aging is 
particularly pertinent to the pulmonary system, which is 
subjected to lifelong challenges by airborne pollutants, 
particulates and pathogens [8]. Similarly, due to the high 
metabolic demand of the heart, large mitochondrial 
population and infrequent cardiomyocyte turnover, the 
heart is also highly susceptible to cumulative oxidative 
damage and stress with age [9]. Cellular and 
immunological changes occur concomitantly with age-
related tissue remodeling.  
There are a great many hallmarks that represent 
common denominators of aging, such as stem cell 
exhaustion, genomic instability, telomere attrition, 
epigenetic alteration and loss of proteostasis [10]; in this 
review we focus on four processes of aging which play an 
integral role in fibrosis. Senescence, inflammaging, 
compromised autophagy and mitochondrial dysfunction 
are interrelated processes, which reduce the regenerative 
capacity of the aged heart and lung, and have been shown 
to be involved in cardiac fibrosis and IPF [5, 11, 12]. As 
a consequence, challenges to an aging heart or lung are 
more likely to lead to pathological tissue remodeling 
rather than wound resolution and tissue restitution. This is 
exemplified in experimental models that show cardiac 
fibrosis in mice post-myocardial infarction increases with 
age [13]. Similarly, pulmonary fibrosis in experimental 





Figure 1. Regulation of senescence growth arrest and the senescence-associated secretory phenotype (SASP) in the aging heart 
and lung. Stresses inducing senescence vary depending on the context, resulting in a variety of effector pathways. However, there is 
considerable overlap in processing of the stress-response signal and activating effectors of senescence, with a common final outcome, 
arrest of cell growth. 
 
1. Cellular senescence  
 
Cellular senescence is an important hallmark of aging [8]. 
Senescent cells are refractory to mitogenic stimuli, a 
consequence of increased levels of the cell-cycle arrest 
proteins p16 INK4a and p21CIPI [15]. These cells also 
acquire a senescence associated-secretory phenotype 
(SASP), an important pathological feature of senescence, 
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characterized by the increased production of 
inflammatory and fibrogenic mediators [16, 17]. Cellular 
senescence is a result of the induction of the p53-p21 
and/or p16-pRB pathways following a DNA damage 
response (DDR) (Fig. 1). One form of senescence, termed 
‘replicative’ senescence, is a consequence of 
chronological aging involving telomere shortening. 
Telomeres are comprised of repetitive DNA sequences at 
the end of chromosomes which protect DNA from 
damage. In somatic cells, telomeres shorten with each 
successive cell division until DNA damage and 
senescence eventuate. ‘Stress-induced’ senescence, also 
involving a DDR, is evoked by cellular insults such as 
oxidative stress, radiation, mutagens and SASP cytokines 
[15-18] as described in Figure 1. Intracellular 
abnormalities such as defects in the telomerase complex 
also contribute to senescence. The contribution of 
senescence in cardiac and pulmonary fibrosis is evidenced 
in clinical and experimental studies. Markers of 
senescence are detected in resident cells of human fibrotic 
heart and lung in situ and after isolation in vitro [18-20]. 
Senescence is evident in cardiac tissue of aged mice at 
baseline and increases in young and aged mice following 
myocardial ischemia-reperfusion injury [20-22]. Cellular 
senescence is also higher in lung tissue of older mice than 
young mice at baseline, and increases in experimental 
lung injury and fibrosis [23]. The selective clearance of 
senescent cells in transgenic mice attenuates age-related 
deterioration of cardiac and lung tissue [24, 25]. 
Furthermore, accelerated senescence prone mice are more 
susceptible to experimental cardiac or pulmonary fibrosis 
than accelerated senescence resistant mice [26, 27]. 
Additionally, senolytic agents, a new class of small 
molecules which target senescent cells, and the selective 
ablation of senescent cells have been demonstrated in 
transgenic ‘Ink Attac’ mice to attenuate lung fibrosis 
following bleomycin instillation [28]. Indeed, several 
senolytic agents, including sirolimus, acarbose, and 
nordihydroguaiaretic acid (NDGA) have been shown to 
extend the lifespan of mice by the National Institute on 
Aging Interventions Testing Program. 
The roles of cellular senescence in cardiac and 
pulmonary fibrosis are complicated, particularly as 
cellular senescence is protective in certain situations (e.g. 
when cells become cancerous and during the early stages 
of tissue injury). Contributing to the ambiguity, cardiac 
fibrosis post-infarction has been shown to be greater in 
p53 and/or p16 knock out mice than wild type mice [29, 
30]. However, these studies were conducted with young 
mice. In experimental models of cardiac or pulmonary 
fibrosis using aged mice, the targeting of senescence 
markers or mediators including Nox4, MMP-9 or 
plasminogen activator inhibitor-1 was protective [14, 20, 
31]. In explaining the increased susceptibility of aged 
mice to pulmonary fibrosis, Thannickal and colleagues 
proposed that pulmonary fibroblasts in young mice don’t 
undergo complete senescence following injury, allowing 
for apoptosis and fibrosis resolution [20]. However, in 
aged mice, the fibroblasts become completely senescent 
after injury, leading to apoptosis resistance and a 
persistent fibrosis. In support, fibroblasts derived from 
aged cardiac or lung tissue are more resistant to apoptosis 
and oxidative-stress induced toxicity than fibroblasts of 
younger tissue [14, 18, 20, 32]. The acquisition of the 
SASP is another important feature of senescent fibroblasts 
that contributes to fibrosis in disease. The hypersecretion 
of proteases, cytokines and fibrogenic mediators by 
senescent fibroblasts would have a large impact on nearby 
non-senescent resident cells, potentially perpetuating the 
fibrotic response. In cardiac disease, fibroblast-derived 
mediators such as TGF-β induce cardiac myocyte 
hypertrophy, which leads to apoptosis via induction of 
apoptosis signaling kinase-1 [33]. In IPF, SASP cytokines 
(e.g. IL-6) and proteases (e.g. urokinase plasminogen 
activator) potentially induce fibroblast and epithelial cell 
senescence in nearby undamaged tissue, or re-inforce the 
senescent phenotype in an autocrine manner [16, 34].  
Overall, cellular senescence can be considered a 
beneficial compensatory response to the damage caused 
by fibrosis and aging when tissues of the heart and lung 
exhaust their regenerative capacity. However, the 
ambiguity regarding the roles of cellular senescence in 
cardiac and pulmonary fibrosis emphasizes the demand 
for further research to fully elucidate the potential 
therapeutic implications behind modulation of senescent 
pathways. Although, with the advent of senolytics that 
either suppress senescence or selectively kill senescent 
cells, the goal of delaying, preventing and alleviating age-
related diseases suggest that it may be possible in the 
future. 
 
2. Inflammaging and immunosenescence 
 
Inflammaging and immunosenescence are interconnected 
age-related processes that also have important roles in 
cardiac and pulmonary fibrosis. Inflammaging describes 
elevated baseline levels of inflammatory markers in 
tissues and the circulation of the elderly in the absence of 
an immunologic threat. Sustained increases in the levels 
of inflammatory cytokines (e.g., IL-6 and TNF-α), 
differentiated lymphocytes and autoantibodies in heart 
and lung tissue, as well as the circulation, mark 
inflammaging in aged humans and rodents [35-38]. As a 
result of prolonged antigenic stress, inflammaging 
contributes to immunosenescence, a delayed but 
protracted immune response to challenge in the elderly. In 
immunosenescence, innate and adaptive immune 
responses such as the phagocytic clearance of cellular 
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debris and lymphocyte activation respectively are 
diminished. Immunosenescence and a corresponding loss 
in immunoregulation is implicated in both fibrotic 
cardiovascular disease (CVD) and IPF [37, 39]. 
Aberration of toll like receptor signaling, which is 
important in the recognition and initiation of adaptive 
immune responses, occurs in CVD and ‘rapidly 
progressive’ IPF [40, 41]. A compromised adaptive 
immune system in biological aging is particularly 
pertinent in myocardial infarction, as the impaired 
clearance of dead myocytes leads to maladaptive tissue 
repair and subsequent pathological tissue remodeling 
[38]. Changes in T-helper cell populations including the 
down-regulation of CD28 (a co-stimulatory molecule for 
T cells) on CD4 cells also occur in CVD and IPF [42, 43]. 
Increases in circulating autoantibodies and 
immunocomplexes are another aspect of 
immuosenescence associated with CVD and the onset of 





Figure 2. Impact of aging on the formation of autolysosome & degradation of contents. Aging increases the cardiomyocyte’s 
need for autophagy to maintain intracellular homeostasis, but simultaneously reduces the activity of lysosomes and thereby inhibits 




Autophagy is an intracellular degradation process 
whereby components of the cytoplasm are degraded in 
lysosomes. Autophagy is required for physiological 
homeostasis and is largely considered a protective 
pathway. Several forms of autophagy have been described 
in mammalian cells, macroautophagy, microautophagy 
and chaperone-mediated autophagy. The term autophagic 
flux refers to the whole process of autophagy, including 
autophagosome formation, maturation, fusion with 
lysosomes, subsequent breakdown and the release of 
macromolecules back into the cytosol [46]. It is often 
described as a measure of autophagic degradation activity 
and a number of methods are currently utilized to assess 
autophagic flux [47]. Macroautophagy is the primary 
pathway and involves the turn-over of redundant or 
damaged cells and proteins, facilitated by 
autophagosomes. This process is tightly controlled by 
autophagy-related proteins (e.g. Atg5, Atg7, microtubule-
associated protein 1 light chain 3 (LC3), Beclin-1) [48]. 
One of the key regulators of macroautophagy in 
mammalian cells is mTOR (mammalian target of 
rapamycin) kinase [49]. Inactivation of mTOR initiates 
autophagy. Macroautophagy is considered the first line of 
attack for cellular stress, with chaperone-mediated 
autophagy increasing after 6-8 hours of prolonged stress 
[50] (Fig. 2).  
Diminished autophagy has been associated with 
several age-related diseases including cancer, 
neurodegeneration, metabolic defects and IPF [51, 52]. 
The specific mechanisms associated with this age-related 
autophagy decline remains unclear. Research suggests 
that a reduction in autophagy accompanies the age-related 
deterioration in cardiac function following myocardial 
infarction [53] and accumulation of dysfunctional 
mitochondria [54, 55], as discussed below.  
Several studies have demonstrated that autophagy 
activity is reduced in IPF lungs and suggest that this 
decrease may induce pro-fibrotic response [56-59]. Patel 
et al demonstrated that autophagy was not induced in 
experimental pulmonary fibrosis despite activation of 
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pathways known to promote autophagy [57]. They 
suggested that TGF-β mediated autophagy impairment 
may represent a mechanism for the promotion of 
fibrogenesis in IPF. Romero et el found that aging 
contributed to lower autophagy induction in primary IPF 
lung fibroblasts compared to young and aged-matched 
controls, and that this was activated by the mTOR 
pathway [58]. Similarly, Sosulski et al demonstrated in 
animal models of pulmonary fibrosis that older mice were 
characterized by reduced autophagy in response to lung 
injury, that autophagy diminished with corresponding 
elevated levels of oxidized proteins and lipofuscin in 
response to lung injury in old mice, and they suggest 
reduced autophagy may contribute to the promotion 
and/or perpetuation of pulmonary fibrosis [59]. 
Furthermore, Araya et al demonstrated in human IPF lung 
fibroblasts that autophagy inhibition can induce 
accelerated epithelial cell senescence and myofibroblast 
differentiation [56].  
In stark contrast to the lung and other fibrotic organs, 
it appears that an increase in autophagy is a major 
regulator of fibrosis in the age-related diseases of the 
heart. Autophagy has been described as a critical factor in 
cardiac fibrosis [60-62] however the specific mechanisms 
by which this occurs are currently under-represented in 
the literature. Boyle et al demonstrated that the 
cardiomyocytes of aging mice displaying cardiac 
dysfunction, fibrosis and hypertrophy exhibited an 
increase in autophagic vacuoles, higher Beclin-1 
expression and increased LC3II:I ratio compared to young 
healthy mice (18 vs 2 months) [63]. Further, Gupta et al 
demonstrated that significant upregulation of autophagy, 
as indicated by increased expression of lipidated LC-3β 
II, occurred concomitantly with fibroblast to 
myofibroblast conversion [61]. They also demonstrated 
that pharmacologic autophagic inhibition repressed the 
myofibroblast conversion. In support, Hariharan et al 
demonstrated that cardiomyocyte death and pathological 
remodeling following experimental myocardial 
ischemia/reperfusion injury and pressure overload 
cardiomyopathy was associated with significantly 
increased autophagy [62]. They also demonstrated that 
inhibition of the pro-autophagic Beclin-1 alleviated the 
effects of the remodeling. This is also indicated in humans 
with Ghavami et al demonstrating that human atrial 
fibroblasts treated with pro-fibrotic stimuli, TGF-β1, had 
increased autophagy in addition to an enhanced fibrogenic 
response [60], and Garcia et al depicting an accumulation 
of autophagic vesicles and lipofuscin deposits with 
electron micrography in the biopsies of the patients 
undergoing coronary artery bypass surgery [64].   
There are multiple lines of evidence suggesting that 
aging is accompanied by impaired autophagy, and that 
this process can provoke fibrosis of the heart and lung in 
both animal models and in vitro models. Therefore, the 
potential benefit up upregulating autophagy as a major 
regulator of age-related diseases, specifically in fibrosis, 
offers a unique treatment option to explore in the future.  
 
4. Mitochondrial dysfunction 
 
Mitochondria are dynamic intracellular organelles found 
in most mammalian cells and are the main source of 
metabolic energy for these cells. As such, they are 
important for the regulation of cellular homeostasis, and 
physiological maintenance of apoptotic signalling 
pathways [65, 66]. Normal functioning and quality 
control of mitochondria depends on the careful balancing 
of two highly regulated and opposing processes: fusion 
and fission. Fusion results in the formation of a single 
mitochondrion from independent structures, whereas 
fission refers to the separation of a mitochondrion into two 
or more daughter organelles [67]. These processes depend 
on the separating of mitochondrial proteins and 
mitochondrial DNA (mtDNA) to enable physiological 
functioning of the individual organelles [67]. 
Mitochondria are highly susceptible to the effects of 
aging, and age-related mitochondrial dysfunction is 
characterized by alterations in structural and functional 
properties including mitochondrial enlargement, loss of 
cristae and the destruction of inner membranes which 
result in disruption to energy production and 
mitochondrial signaling [65, 66, 68]. The mitochondrial 
theory of aging proposes that intracellular reactive oxygen 
species (ROS), primarily produced by mitochondria as a 
by-product of cellular respiration, mutates mtDNA. ROS 
production is known to increase with age, and subsequent 
somatic accumulation of these mutations are thought to 
contribute to the aging phenotype [65, 66, 69]. Indeed, 
mitochondrial-targeted catalase has been shown to reduce 
obesogenic-stress induced left ventricular hypertrophy 
[70] and halt age-related ventricular fibrosis, 
mitochondrial protein oxidation, mDNA mutations [70].   
Certain animal models of mitochondrial aging utilize 
a strain of mice possessing a knock-in of the mtDNA 
polymerase: polymerase gamma (PolgD257A/D257A). The 
resulting missense mutation causes a decline in 3’-5’ 
exonuclease activity, which reduces the proofreading 
efficiency of DNA synthesis, and consequently 
compromises genetic stability [69, 71]. These 
homozygous mice accumulate more somatic mtDNA 
mutations over the span of their lifetime. This corresponds 
with a significantly reduced lifespan and a progeroid 
phenotype including typical signs of physiological human 
aging such as enlargement of the left ventricle and 
development of cardiomyopathy, alopecia, anaemia, 
frailty, kyphosis, osteoporosis, sarcopenia, testicular 
atrophy, weight loss, reduced sub-cutaneous fat, reduced 
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fertility, and a decline in haematopoietic stem cell 
production [65, 69, 72, 73]. Data obtained from these 
animals advocates a causative role for mtDNA mutations 
in physiological aging and indicate this may also 
contribute to the pathogenesis of fibrotic diseases that 
develop with age, including various cardiomyopathies, 





Figure 3. Alterations in dysfunctional mitochondria in the aging or diseased heart and lung. Reduction in the ability of 
dysfunctional mitochondria in the heart and lung to create energy causes an energy deficit that disrupts physiological cellular functioning. 
Mitochondrial dysfunction in the aging heart and may result in the development of mitochondrial cardiomyopathy or IPF respectively. 
Mitochondrial dysfunction induced by an acute event in the heart significantly disrupts the contraction and relaxation of contractile cells 
in the heart and perpetuates a cycle of detrimental effect. 
 
The heart and lung both have a high demand for 
metabolic activity, and as such are densely populated by 
mitochondria. Physiological functioning of these organs 
relies heavily on the regulation of cellular-energetic 
homeostasis and mitochondrial function [66]. Impaired 
mitochondrial function has been identified in the heart and 
lungs of healthy aging individuals and diseased aging 
patients (Fig. 3) [74, 75]. For example, a reduction in the 
energy output of cardiac mitochondria, increased ROS 
production, and suppressed mitophagy has been shown to 
accompany cardiac senescence induced by physiological 
aging. This results in the accumulation of defective 
mitochondria, and interruptions to the processes of fission 
and fusion [66]. These disruptions can result in the 
development of mitochondrial cardiomyopathy, a 
myocardial disorder characterized by abnormal 
myocardial structure or function in the absence of 
concomitant coronary artery disease, hypertension, 
valvular disease, and congenital heart disease [75]. An 
acute cardiac event on the other hand initiates a sequence 
of events that results in the gradual decline of the energy 
reserve capacity of the heart [76]. Several compensatory 
mechanisms are activated to promote normal functioning 
and blood circulation; however, when the energy reserve 
capacity reaches critical levels, these mechanisms are no 
longer sufficient to maintain physiological functioning 
and ultimately results in heart failure [76, 77]. This 
reduces the ability of mitochondria to produce and 
transfer energy within cardiac cells, thus creating an 
energy deficit, which leads to a decline in the contraction 
and relaxation capacity of contractile cells within the 
heart, and consequently perpetuates a cycle of detrimental 
effects [76]. 
Comparably, mitochondrial dysfunction in the form 
of mitochondrial enlargement, increase of mitochondrial 
area in aging type II alveolar epithelial cells (AECIIs), and 
a bias towards fusion has been identified in the aging and 
IPF lung [68, 74]. There is a general consensus that 
endoplasmic reticulum (ER) stress induced abnormalities 
in AECIIs causes irregular re-epithelialisation, secretion 
of pro-fibrotic cytokines, and fibroblast activation; 
ultimately leading to the development of IPF [74]. AECIIs 
are a highly metabolic cell population, which account for 
approximately half of the total mitochondrial content of 
the lung [74]. Bueno et al demonstrated that AECIIs in 
highly fibrotic regions of IPF lungs accumulate 
dysfunctional mitochondria and exhibit impaired 
autophagy relative to AECIIs from regions of moderate to 
mild fibrosis, and control donors. This study also 
established that age (18-24 months) and ER stress alters 
mitochondrial function in AECIIs isolated from C57BL/6 
mice, as determined by reduction in mitochondrial 
respiration, loss of cell viability and activation of pro-
fibrotic responses relative to young (3 months) mice [74]. 
It has been shown that dysfunctional mitochondria in 
AECIIs of aging or ER stress exposed animals correlates 
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with the reduced expression of PTEN-induced putative 
kinase 1 (PINK1), a regulator of mitochondrial 
homeostasis [68, 74]. PINK1 deficient mice demonstrated 
apoptosis and TGF- mediated fibrosis of the lungs, 
accompanied by structural and functional alterations of 
mitochondria in AECIIs; consequently, these animals 
were more prone to lung injury and fibrosis [68, 74, 78]. 
Asides from AECII cells, Trujillo and colleagues recently 
showed fibroblasts of lung tissue from IPF patients have 
increased mitochondrial mass, and that IPF-derived lung 
fibroblasts, when compared to cells from control donors, 
release increased amounts of mtDNA in vitro [79]. 
Importantly, they showed higher levels of mtDNA in the 
bronchoalveolar lavage and serum of IPF patients, 
compared to control donors, and serum levels of mtDNA 
were predictive of all-cause mortality.  By virtue of its 
bacterial ancestry and many specific characteristics such 
as hypo-methylation, unique structural features and 
exaggerated susceptibility to oxidative damage, mtDNA 
can be a potent damage associated molecular pathogen 
(DAMP) capable of triggering a paracrine inflammatory 
response by activating inflammasomes (in particular 
NLRP3) or toll-like receptors (i.e. TLR9) and other DNA 
binding receptors (i.e. cyclic GMP-AMP synthase 
[cGAS]) of the innate immune system [80]. 
Sirtuin 3 (SIRT3) is a mitochondrial protein 
deacetylase regulator of antioxidant response and 
mitochondrial homeostasis, known to be an age-related 
pathogenic mechanism in heart and lung fibrosis. Sosulski 
et al  demonstrated reduced SIRT3 expression in the lungs 
of old mice compared to young mice, as well as in two 
murine models of pulmonary fibrosis [81]. Mice lacking 
sirtuin 3 (SIRT3KO), have increased acetylation and 
inhibition of many mitochondrial enzymes and 
complexes, suppressing mitochondrial function. Sirt3KO 
mice develop spontaneous pulmonary arterial 
hypertension (PAH) [82] and cardiac fibrosis [83]. 
Interestingly, Chen et al demonstrated that SIRT3 
activation with RSV in vitro and in vivo ameliorated 
collagen deposition, preventing cardiac fibrosis and 
improving cardiac function in mice.  
Overall, these observations suggest that 
mitochondrial dysfunction is likely to play a key role in 
the development of fibrotic conditions and can accelerate 
the process of aging. However, the therapeutic potential 
of targeting pathways such as activation of SIRT3 via the 
TGF-β/Smad3 pathway offer exciting new avenues to 




Aging is an important predisposing factor for fibrotic 
heart and respiratory diseases. Age-related processes such 
as senescence and inflammaging diminish the 
regenerative capacity of damaged cardiac and pulmonary 
tissue, increasing the likelihood of pathological fibrosis 
following injury or challenge. What is interesting about 
these two processes is that at low levels, they mediate 
beneficial effects, but as you age and the level increases, 
they become deleterious. This is most evident with 
senescence, which protects the organism from cancer but 
which, in excess, can promote aging and the hallmark 
features of fibrosis. Furthermore, inflammaging and its 
sustained increase of inflammatory markers, which at 
normal levels regulate the immune response, contributes 
to the acquired resistance of myofibroblasts to apoptosis, 
and the low grade chronic inflammation which sustains 
the persistent fibrosis of CVD and IPF.  
Recycling through autophagy, may offer a 
pharmacological target in age-related lung and heart 
fibrotic diseases. However, as described above further 
investigations are required to fully understand the 
mechanisms of chronic fibrosis, importantly the 
contrasting effects of autophagy dysregulation in the heart 
and lung. Finally, promotion of mitochondrial turnover 
and a prevention of the imbalances to fission and fusion 
that trigger that mitochondrial dysfunction may play a key 
role in preventing the development of fibrotic conditions 
and the process of aging as demonstrated with SIRT3 
activation and the improved collagen deposition.  Given 
the similarities between cardiac and pulmonary fibrosis, 
investigating targets and testing future treatments in both 
organs with a focus on these key age-related processes 
seems justifiable and may lead to better treatment 
opportunities for age-related cardiac and pulmonary 
fibrosis. We conclude that ever more sophisticated 
approaches, and an ever-expanding understanding of the 
mechanisms underlying the hallmarks of aging will 
facilitate future interventions for improving human 
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